Acupuncture Reduces Side Effects of Breast Cancer Treatment as Much as Conventional Drug Therapy

Publication
Article
OncologyONCOLOGY Vol 22 No 11
Volume 22
Issue 11

Acupuncture is as effective and longer-lasting in managing the common debilitating side effects of hot flashes, night sweats, and excessive sweating (vasomotor symptoms) associated with breast cancer treatment and has no treatment side effects compared to conventional drug therapy, according to a first-of-its-kind study presented September 24, 2008, at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston.

Acupuncture is as effective and longer-lasting in managing the common debilitating side effects of hot flashes, night sweats, and excessive sweating (vasomotor symptoms) associated with breast cancer treatment and has no treatment side effects compared to conventional drug therapy, according to a first-of-its-kind study presented September 24, 2008, at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston.

Findings also show there were additional benefits to acupuncture treatment for breast cancer patients, such as an increased sense of well-being, more energy, and in some cases, a higher sex drive, that were not experienced in patients who underwent drug treatment for their hot flashes.

More Durable Than Drug Effect

“Our study shows that physicians and patients have an additional therapy for something that affects the majority of breast cancer survivors and actually has benefits, as opposed to more side effects. The effect is more durable than a drug commonly used to treat these vasomotor symptoms and, ultimately, is more cost-effective for insurance companies,” Eleanor Walker, md, lead author of the study and a radiation oncologist at the Henry Ford Hospital Department of Radiation Oncology in Detroit, said.

The reduction in hot flashes lasted longer for those breast cancer patients after completing their acupuncture treatment, compared to patients after stopping their drug therapy plan. Approximately 80% of women treated for breast cancer suffer from hot flashes after being treated with chemotherapy and/or antiestrogen hormones, such as tamoxifen and anastrozole (Arimidex). Although hormone replacement therapy is typically used to relieve these symptoms, breast cancer patients cannot use this therapy because it may increase the risk of the cancer coming back. As a treatment alternative, patients are generally treated with steroids and/or antidepressant drugs. These drugs, however, have additional side effects, such as weight gain, nausea, constipation, and fatigue.

Acupuncture vs Venlafaxine

The antidepressant venlafaxine (Effexor), a selective serotonin-reuptake inhibitor, is one of the most common drugs used to treat these hot flashes. However, many women decide against this treatment choice because of potential side effects, including decreased libido, insomnia, dizziness, and nausea, or because they simply do not want to take any more medications.

The randomized clinical trial compared acupuncture treatment to venlafaxine for 12 weeks to find out if acupuncture reduced vasomotor symptoms in breast cancer patients receiving hormonal therapy and produced fewer side effects than venlafaxine. The investigation involved 47 breast cancer patients who received either tamoxifen or anastrozole and had at least 14 hot flashes per week. Results of the trial show that acupuncture reduces hot flashes as effectively as venlafaxine, with no side effects. In addition, acupuncture provides additional health benefits to patients.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.